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Abstract
Background: The protozoan parasite Cryptosporidium parvum is responsible for significant disease burden among children
in developing countries. In addition Cryptosporidiosis can result in chronic and life-threatening enteritis in AIDS patients,
and the currently available drugs lack efficacy in treating these severe conditions. The discovery and development of novel
anti-cryptosporidial therapeutics has been hampered by the poor experimental tractability of this pathogen. While the
genome sequencing effort has identified several intriguing new targets including a unique inosine monophosphate
dehydrogenase (IMPDH), pursuing these targets and testing inhibitors has been frustratingly difficult.
Methodology and Principal Findings: Here we have developed a pipeline of tools to accelerate the in vivo screening of
inhibitors of C. parvum IMPDH. We have genetically engineered the related parasite Toxoplasma gondii to serve as a model
of C. parvum infection as the first screen. This assay provides crucial target validation and a large signal window that is
currently not possible in assays involving C. parvum. To further develop compounds that pass this first filter, we established
a fluorescence-based assay of host cell proliferation, and a C. parvum growth assay that utilizes automated high-content
imaging analysis for enhanced throughput.
Conclusions and Significance: We have used these assays to evaluate C. parvum IMPDH inhibitors emerging from our
ongoing medicinal chemistry effort and have identified a subset of 1,2,3-triazole ethers that exhibit excellent in vivo
selectivity in the T. gondii model and improved anti-cryptosporidial activity.
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Introduction
Gastrointestinal diseases remain the largest threat to the health
of infants and small children in environments with low income and
poor sanitation. While acute diarrheal disease claims numerous
lives, chronic or recurrent forms can result in stunting of physical
and intellectual growth in an even larger number of children. The
aetiology of diarrheal disease in children is complex, involving a
large group of viral, bacterial, protozoan and metazoan pathogens.
Among these the protozoan parasites, Cryptosporidium parum and
hominis are epidemiologically important pathogens [1,2].
Cryptosporidium causes acute self-limiting gastrointestinal disease in
healthy individuals. Immunity is slow to develop and the disease can
be recurrent and protracted in malnourished children [3–6].
Malnourished children are not only more susceptible to severe
cryptosporidiosis, but the disease itself is an important contributing
factor to malnutrition [7]. In immunocompromised individuals like
those suffering from AIDS, cryptosporidiosis is a chronic and life-
threatening disease [8]. The persistent and resilient nature of the
infective oocyst stage in drinking and recreational water poses
significant challenges for controlling transmission even in industri-
alised nations. No vaccines exist, and the currently available drugs
are inadequate. The more widely used drugs paromomycin and
azithromycin are unreliable and the efficacy of nitazoxanide, which
recently received FDA approval, is dependent upon a robust
immune response [9]. The options in particular for the treatment of
chronic AIDS-related cryptosporidiosis are severely limited [10]
and there is an overall urgent need for new chemotherapy.
The sequencing of the genomes of Cryptosporidium parvum and
hominis revealed a highly streamlined anabolic metabolism with
potential choke points that might be exploited in drug design
[11,12]. One such vulnerability lies in the pathway that supplies
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protozoan parasites, Cryptosporidium is incapable of de novo purine
synthesis and relies on salvage of purines from the host. While many
parasites, including the related Apicomplexa Toxoplasma and
Plasmodium, use hypoxanthine-xanthine-guanine phosphoribosyl-
transferase (HXGPRT, Figure 1) to salvage a broad range of purine
bases this enzyme is missing in Cryptosporidium [12,13]. Instead,
Cryptosporidium relies solely on the salvage of adenosine to provide
both adenine and guanine nucleotides. This simplified pathway is
initiatedbyadenosine kinaseand criticallydependsontheactivityof
inosine monophosphate dehydrogenase (CpIMPDH). Surprisingly,
the CpIMPDH gene appears to have been acquired through lateral
gene transfer from an e-proteobacterium [13,14]. Detailed kinetic
analysis of this prokaryote-like enzyme demonstrated that
CpIMPDH is very different from its human homologs [13,15].
The ‘‘drugability’’ of IMPDH is well established as inhibitors of
human IMPDHs have been used clinically as immunosuppressants
as well as for the treatment of viral infections and cancer [16–18].
Taken together, these observations suggest that CpIMPDH is a
promising therapeutic target for cryptosporidiosis [13–15,19].
We have recently discovered several new classes of selective
inhibitors of CpIMPDH in a high throughput screen [20].
Extensive medicinal chemistry optimization has produced nano-
molar inhibitors with greater than 10
3-fold selectivity for
CpIMPDH over the human enzymes [21,22]. Further elaboration
of these compounds requires a rapid and reliable assay to evaluate
their anti-parasitic activity. The screening of compounds against
C. parvum has proven challenging and the main roadblock in our
drug development program. This is partly because the parasite
cannot be cultured continuously in tissue culture. Although several
growth assays have been developed, including real-time PCR
protocols [23–28], immunoassays [29,30], and image analysis
routines [31], these assays are labour intensive and expensive, or
are not amenable to higher throughput. The scarcity of
experimental tools for C. parvum also makes it difficult to investigate
the mechanism of inhibitor action.
In this study we describe an assay pipeline to evaluate the anti-
cryptosporidial activity of CpIMPDH inhibitors in tissue culture
models. We have genetically engineered the related apicomplexan
parasite T. gondii to mirror the purine pathway of Cryptosporidium
and to depend on CpIMPDH for survival. This system provides a
rapid assessment of anti-parasitic potential and a quantitative read
of target specificity. To further evaluate if anti-cryptosporidial
activity arises from off-target effects on the host cell, we devised a
simple and highly sensitive host cell growth assay using an HCT-8
line engineered to express a yellow fluorescent protein. Lastly, we
have developed a new high-content imaging assay to measure
C. parvum proliferation directly. We have utilized these assays to
probe the structure-activity relationship for a series of CpIMPDH
inhibitors [20,22]. We discovered five compounds that exhibited
potency and selectivity in the T. gondii model, including two that
show sub-micromolar anti-cryptosporidial activity.
Materials and Methods
Cosmid modification
Cosmid TOXOU05 [32] was selected using the ToxoDB
database [33]. The 42.2 Kb genomic DNA insert of TOXTOU05
spans the TgIMPDH open reading frame with 14.3 Kb and
Figure 1. Schematic of purine salvage in T. gondii and C. parvum.
A, Genetic studies have shown that the salvage of adenosine via
adenosine kinase is the predominant route to GMP for T. gondii [59] and
IMPDH catalyses the rate limiting step of this pathway. However in the
absence of adenosine kinase, TgHXGPRT allows for the salvage of
adenosine, adenine and guanosine such that the activity of TgHXGPRT
is sufficient for parasite proliferation [59]. Several transporters for the
uptake of nucleobases [60] and nucleotides have been characterised in
T. gondii [60–62]; B) Unlike T. gondii and other Apicomplexa, C. parvum
lacks HXGPRT [12,13] and is dependent on the salvage of adenosine and
thus the activity of CpIMPDH. A single adenosine transporter has been
identified in the genome of C. parvum [12,59]. The T. gondii pathways
shown in grey in A highlight the genes disrupted in the parasite clones
used in this study, TgHXGRT in a previous studies (HXGPRT;[41]) and
TgIMPDH in this study. Hyp, hypoxanthine; Xan, xanthine; Gua, guanine;
Guo, guanosine; Ade, adenine; Ado, adenosine; Ino, inosine; AMP,
adenosine monophosphate; IMP, inosine monophosphate; XMP,
xanthosine monophosphate; GMP, guanosine monophosphate;
HXGPRT, hypoxanthine xanthine gunanine phosphoribosyltransferase;
IMPDH, IMP dehydrogenase, 1, adenine deaminase; 2, adenosine
deaminase; 3, purine nucleoside phosphorylase; 4, adenosine kinase;
5, AMP deaminase; 6, adenoylsuccinate synthase and adenoylsuccinate
lyase; 7, GMP synthase [13,59,63].
doi:10.1371/journal.pntd.0000794.g001
Author Summary
Persistent diarrhea is a leading cause of illness and death
among impoverished children, and a growing share of this
disease burden can be attributed to the parasite Crypto-
sporidium. There are no vaccines to prevent Cryptosporid-
ium infection, and the treatment options are limited and
unreliable. Critically, no effective treatment exists for
children or adults suffering from AIDS. Cryptosporidium
presents many technical obstacles for drug discovery;
perhaps the most important roadblock is the difficulty of
monitoring drug action. Here we have developed a set of
methods to accelerate the drug discovery process for
cryptosporidiosis. We exploit the opportunities for exper-
imental manipulation in the related parasite Toxoplasma to
genetically engineer a Cryptosporidium model. This new
model parasite mirrors the metabolism of Cryptosporidium
for a particularly promising drug target that supplies the
building blocks for DNA and RNA. Drug effectiveness can
be assayed through simple fluorescence measurements for
many candidates. Using this assay as an initial filter, and
adapting other assays to a high throughput format, we
identify several novel chemical compounds that exhibit
markedly improved anti-cryptosporidial activity and excel-
lent selectivity.
Drug Screening for Cryptosporidium
www.plosntds.org 2 August 2010 | Volume 4 | Issue 8 | e79422.7 Kb of flanking sequence at the 59 and 39 ends respectively. A
schematic overview of the cosmid modification steps is shown in
Figure S1 [34]. Initial cosmid amplification was performed in E. coli
strain XL1Blue using LB containing 10 mg/ml kanamycin. The
QIAprep Spin Miniprep kit (QIAGEN) was used with slight
modification to the standard protocol for cosmid purification.
Following the addition of buffer P3 and centrifugation cosmid
DNA was directly precipitated from the supernatant using 0.7
volumes of isopropanol. Cosmid DNA (200 ng) was introduced
into the E. coli EL250 strain [35] by electroporation (ECM 630,
1 mm cuvette, 1.75 kV, 250 V, and 25 mF; BTX; Holliston, MA)
and bacteria were propagated in LB (50 mg/ml kanamycin) and
rendered electro-competent. A cassette, comprising a bacterial
gentamycin selectable marker and the chloramphenicol resis-
ftance gene flanked by the 59 and 39 UTRs of the T. gondii GRA1
gene (for selection in the parasite) was amplified from plasmid
piCG [34] by PCR. To drive recombination between the cosmid
and the GENTgraCATgra cassette to excise the IMPDH coding
sequence, ,50 bp overhangs homologous to the sequence
immediately flanking the start and stop codons of the TgIMPDH
gene were included in the primers (primers 973: 5-
(CCTGCGTCGTTTTTGCCTCGTGGCTGTTTGGCTTGT-
GGGTGTCTTTCCACATACGACTCACTATAGGGCGAA-
TTGG) and 923: 59- GTTCCCCTTTTTATATTTCTTC-
TTCCGTTGCACTTCCCCAGCGAAACAAAATACGACTC-
ACTATAGGGCGAATTGG). The PCR amplified cassette was
gel purified and 200 ng were electroporated into the EL250 strain
[35] bearing the TOXO05 parent cosmid and bacteria were
selected using kanamycin (50 mg/ml) and gentamycin (10 mg/ml).
To recycle the bacterial gentamycin selectable marker, the
sequence was removed from the modified cosmid using flanking
Flp sites and induction of flipase [34]. Cosmid DNA was isolated
from kanamycin resistant, gentamycin sensitive clones and the
removal of the gentamycin sequence was confirmed by PCR. To
exchange the parasite selectable marker DHFR with the
fluorescent marker YFYFP the tubYFPYFPmicGENT expression
cassette was recombineered into the TOXOU05graCATgra-
DIMPDH cosmid in EL250 E. coli following the method described
above. The tubYFPYFPmicGENT cassette was amplified from the
pYG plasmid using primers (874: 59-GTTCCCCTTTTTA-
TATTTCTTCTTCCGTTGCACTTCCCCAGCGAAACAAA-
ATACGACTCACTATAGGGCGAATTGG and 875: 59- GTC-
GTGGGCAGACAGCAACAGTCCAGCACTCTAGCGGCATA-
CAGAACGATCTTCTTAGGTGGCGGTACTTGGGTC). Ap-
proximately 50 bp overhangs homologous to the sequence
flanking the DHFR coding sequence were included in these
primers to drive recombination to create TOXOU05CAT-
DIMPDHYFPYFP. Restriction enzymes HindIII, NdeI and NotI
were used to confirm appropriate recombination in the final
cosmid DNA preparation.
Targeting the TgIMPDH locus
T. gondii RHDHX-CpIMPDH-5MX clone [14] was electropo-
rated with 25 mg of circular TOXOU05CATDIMPDHYFPYFP
cosmid (Figure S1). The parasites were cultured in hTERT cells
and selected under 6.8 mg/ml chloramphenicol as described
previously [36]. Chloramphenicol resistant parasite clones were
PCR screened using 2 primer pairs to the graCATgra cassette and
2 primer pairs to the TgIMPDH coding sequence and a single
primer pair to the tubYFPYFPmicGENT cassette. This PCR
screen indicated that double-homologous recombination at the
TgIMPDH locus had occurred in 2 clones. Southern blotting
confirmed that double homologous recombination had occurred
to replace the native TgIMPDH locus with the graCATgra
expression. Probe 1 was amplified from wild-type T. gondii genomic
DNA using primers 1108 (59-CGATGTCGGGGAATCACA-
AGCGAGAACA) and 1109 (59-ATGTCTTCTACGAARGC-
GRGAGTGGTGC).
Isolation of fluorescent T. gondii parasite and fluorescent
growth assay
Wild-type T. gondii and T. gondii-DHXGPRT parasites were
transfected with plasmid ptubYFPYFsagCAT [37] which drives
constitutive cytoplasmic expression of two copies of the yellow
fluorescent protein. Similarly, plasmid pCTR2T [38] was
transfected into T. gondii-CpIMPDH resulting in constitutive
cytoplasmic expression of a tandem of the tomato variant of the
red fluorescent protein [39]. Fluorescent parasites were selected
and cloned by cell sorting using a MoFlo Legacy instrument
(Beckman Coulter, Inc). Growth of fluorescent clones was
monitored in 96 well plates as previously described [37]. Briefly,
fluorescence was read daily with a SpectraMax M22/M2e
(Molecular Devices) plate reader (Ex 485, Em 530) for 6–7 days.
For each of the three fluorescent T. gondii clones percent growth
inhibition was calculated on a day within the exponential phase of
growth for the purpose of determining an IC50 for each
compound.
Southern blotting
T. gondii genomic DNA was extracted using the DNeasy kit
(QIAGEN). 1.0 mg of genomic DNA and 2.5 ng of cosmid DNA
was digested for 14 hours with Xho1 and separated on a 0.9%
TBE agarose gel and transferred overnight by downward transfer.
The blot was hybridized over night with probe 1, which was
amplified from wild-type T. gondii genomic DNA using primers
1108 (59-CGATGTCGGGGAATCACAAGCGAGAACA) and
1109 (59-ATGTCTTCTACGAARGCGRGAGTGGTGC).
In vitro culture of Cryptosporidium parvum
The human ileocecal adenocarcinoma epithelial cell line, HCT-
8, was used to support C. parvum infection in vitro. HCT-8 cells were
maintained in RPMI-1640 (Hyclone) supplemented with 10%
FBS, 1 mM sodium pyruvate, 50 U/m penicillin, 50 mg/ml
streptomycin, and amphotericin B. Cryptosporidium parvum oocysts
were a kind gift from either Dr. Mead (Emory University) or Dr.
Kissinger (University of Georgia). HCT-8 cells (2610
5) were
seeded into black, optical quality, thin bottom, 96-well plates (DB
Falcon) to achieve a 70% confluent monolayer on the day of
infection. To facilitate oocyst excystation, a procedure described
by Gut et al., was followed. Briefly, oocysts were washed twice with
1 ml of PBS (pH 7.2), incubated for 10 minutes at 37uCi n1m l
10 mM of HCl and then incubated for a further 10 minutes in
0.2 ml of 200 mM sodium taurocholate at 15uC [40]. This oocyst
suspension was diluted directly with DMEM (Hyclone) supple-
mented with 2% FBS, 50 U/ml penicillin, 50 mg/ml streptomy-
cin, amphotericin B and 0.2 mM L-glutamine (infection medium)
to inoculate host cell monolayers at 5610
5 oocysts per well. Host
cell monolayers were incubated for 3 hours at 37uC prior to
removal of unexcysted oocysts by aspiration and PBS wash.
Infection medium was then added to the monolayers and infection
was allowed to progress for 48 hours.
Vicia villosa lectin (VVL) immunofluorescence assay and
high content imaging
The VVL IFA was performed in a 96-well format. Following
48 hours of culture C. parvum infected HCT-8 cells were washed
with PBS and fixed with 0.2 ml/well of 3% paraformaldehyde/
Drug Screening for Cryptosporidium
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with 4% BSA/PBS. 0.1 ml of fluorescein (FITC)-conjugated VVL
(Vector Labs 0.5 mg/ml) in 1% BSA/PBS was applied to wells and
incubated for 45 minutes. The plates were washed twice with
200 ml/well of PBS. In the first wash DAPI was included at
0.1 mg/ml. Finally 200 ml/well of PBS was added to the plates
prior to storage at 4uC protected from light.
Confocal images were acquired using a BD Biosciences
Bioimager P435. The instrument was programmed to automat-
ically change position and focus, capture montage images of 9–16,
406fields per well, and then compress and save the image files.
Object finding algorithms were developed for the recognition of
FITC-VVL labelled C. parvum parasites and DAPI labelled host
cell nuclei using Attovision Software (BD Biosciences). Briefly, to
identify FITC-VVL labelled parasites, the object finding algorithm
included, a flat field correction, a polygon shape setting, a 363
rolling ball filter, manual pixel intensity thresholding (100 min –
4095 max), and minimum and maximum object size cut-offs of 5
pixels and 350 pixels respectively. The algorithm optimised for
finding DAPI labelled host cell nuclei also included flat field
correction and polygon shape setting, but applied a 25625 rolling
ball filter which is more suitable for larger objects, an automated
pixel intensity threshold, minimum and maximum object size
cut-offs of 200 pixels and 4000 pixels respectively, and a water-
shed step with an erosion factor of 8 to aid in the separation of
adjacent densely packed nuclei. Note that the intensity and area
size cut off exclude detection of the much smaller parasite nuclei
(the human genome is three hundred times larger than the
C. parvum genome).
The object finding analysis steps described above recorded the
number and area of objects per montage image. The output files
along with a plate map file were then passed to an automated
analysis pipeline (Pipeline Pilot Software, Accelrys) to calculate the
mean number of parasites, the ratio of parasite number to host
cell nuclei number, the mean area of parasites and host cell nuclei
by well, and the percentage growth by treatment as compared to
the no drug control. These analyses were exported in graphical
format for each plate and the numerical values tabulated in html
format.
All test compounds were stored as 0.1 M stocks in DMSO at
220uC and further diluted in DMSO to a 2006working stocks for
each dilution, such that the final concentration of DMSO in the
infection medium was uniformly 0.5%. For the no drug control,
DMSO alone was added to triplicate wells. As a control, a high
paromomycin concentration (0.8 mg/ml) was included on each
plate in triplicate wells. Plates where this paromomycin control did
not inhibit 70–80% of parasite growth were manually inspected
and omitted from the final analysis. To control for potential false-
positive parasite detection uninfected wells were scored in each
plate and the typically low background counts were automatically
subtracted from the test wells.
Fluorescent HCT-8 host cell growth assay
HCT-8 cells were transfected with plasmid pmaxGFP (Amaxa)
using Lipofectamine (Invitrogen). Fluorescent lines were then
selected and cloned using cell sorting. Confluent monolayers of
pmaxGFP expressing cells were harvested from T75 flasks and
passed through a 40 mm cell strainer. Cells were seeded at 4000
cells per well into black, optical quality, thin bottom, 96-well
plates. All test compounds were diluted in DMSO as described.
The fluorescence was read daily with a SpectraMax M22/M2e
(Molecular Devices) plate reader (Ex 485, Em 530) for 6–7 days.
Percent inhibition was calculated on a day within the exponential
phase of growth.
Compound synthesis
All compounds were synthesized using procedures previously
described [22]. Compounds A61, A64, A68 and A99 were not
previously described. The NMR spectra for these compounds are
included as Supplemental Materials S1.
Results and Discussion
Engineering a Toxoplasma reporter parasite suitable for
the screening of CpIMPDH inhibitors
To facilitate screening of antiparasitic activity, we constructed a
T. gondii reporter parasite that mirrors the Cryptosporidium purine
metabolism. Figure 1 summarizes the main differences between
the two parasites in this pathway. We started with a T. gondii
knockout mutant that, like C. parvum, lacks the ability to salvage
xanthine and guanine via HXGPRT (T. gondii-DHXGPRT [41])
and introduced the CpIMPDH gene under the control of a T. gondii
promoter [14]. Next the native T. gondii IMPDH gene was
disrupted by replacing the entire coding sequence with a
chloramphenicol acetyl transferase cassette using a new cosmid-
based gene targeting approach [34]. The recombineering
procedure used to modify a cosmid of the IMPDH genomic locus
is summarized in Figure S1. Successful disruption of the gene was
confirmed by PCR (data not shown) and Southern blotting
(Figure 2A & B); note that numerous previous attempts to target
this locus using smaller plasmid-based constructs failed. This
manipulation created strain T. gondii-CpIMPDH-DHXGPRT-
DTgIMPDH. Lastly, we introduced a fluorescent protein cassette
and isolated stable transgenic parasites by cell sorting. The
resulting strain is referred to as T. gondii-CpIMPDH. The growth of
this new parasite can be conveniently monitored in live cultures in
96 or 384 well format using a fluorescence plate reader [37]. We
similarly engineered fluorescent versions of wild-type T. gondii and
T. gondii-DHXGPRT to serve as controls.
Pharmacological validation of the Toxoplasma reporter
parasite
To determine if the proliferation of T. gondii-CpIMPDH depends
on CpIMPDH as designed, we performed fluorescence growth
assays in the presence of varying concentrations of mycophenolic
acid (MPA), comparing wild-type T. gondii, DHXGPRT, and
CpIMPDH parasites (Figure 3A, D &G). MPA is a potent inhibitor
of eukaryotic IMPDHs including TgIMPDH [17,42] but a very
poor inhibitor of prokaryotic IMPDHs. CpIMDPH is of
prokaryotic origin and not inhibited by MPA at concentrations
active against TgIMPDH [14,15]. As predicted, both wild-type
T. gondii and T. gondii-DHXGPRT are sensitive to MPA (Figure 3B
& E; [13,14,42]), but T. gondii-CpIMPDH is resistant (Figure 3H).
T. gondii-DHXGPRT is the most sensitive strain due to its inability
to salvage xanthine/guanine from the media (EC50=0.29 mM
versus 2.6 mM for the wild-type strain; Figure S2 details how an
EC50 value was derived from the parasite growth curves).
Supplementation of the media with xanthine (0.33 mM) essentially
renders wild-type T. gondii MPA resistant (Figure 3C;
EC50$78 mM), but has no effect on T. gondii-DHXGPRT
(Figure 3F). In contrast, T. gondii-CpIMPDH is resistant to MPA
in the absence of xanthine (EC50.65 mM), as expected given the
resistance of the prokaryotic CpIMPDH (Figure 3G & I; [15]).
These results demonstrate that the T. gondii model system
provides a powerful tool for the evaluation of in vivo efficacy,
selectivity, and specificity of CpIMPDH inhibitors. Compounds
that selectively inhibit CpIMPDH will block the proliferation of
T. gondii-CpIMPDH but not the wild-type and T. gondii-
DHXGPRT strains that depend on an eukaryotic IMPDH much
Drug Screening for Cryptosporidium
www.plosntds.org 4 August 2010 | Volume 4 | Issue 8 | e794Figure 2. Disruption of TgIMPDH to generate a T. gondii parasite dependent on CpIMPDH. A shows a Southern blot confirming the
replacement of the native TgIMPDH coding sequence. Genomic parasite DNA or purified cosmid DNA was digested with XhoI, subjected to
electrophoresis and blotting, and hybridized with a probe specific to the region shown in B.I nA, lane 1 shows the wild-type cosmid TOXOU05, lane 2
the knock-out cosmid TOXOU05CATDIMPDHYFPYFP, lane 3 the parent parasite T. gondii RHDHX-CpIMPDH-5MX, lane 4 the T. gondii-CpIMPDH-
DHXGPRT-DTgIMPDH knock-out parasite, and lane 5 a merodiploid transformant that retained the native TgIMPDH locus. Note that T. gondii-
CpIMPDH-DHXGPRT-DTgIMPDH is hereafter referred to as T. gondii-CpIMPDH.
doi:10.1371/journal.pntd.0000794.g002
Figure 3. Validation of the T. gondii-CpIMPDH reporter parasite. Schematic representation of the routes to GMP for the wild-type T. gondii,
T. gondii-DHXGPRT, and T. gondii-CpIMPDH are shown in A, D & G respectively. B, E & H show parasite growth in the presence of 0 mM and 7.8 mM
MPA for wild-type T. gondii, T. gondii-DHXGPRT, and T. gondii-CpIMPDH respectively. C, F, and I show parasite growth curves in the presence of 0 mM
and 7.8 mM MPA, with the addition of 0.33 mM xanthine to the culture media, for wild-type T. gondii, T. gondii-DHXGPRT, and T. gondii-CpIMPDH
respectively. Data are representative of 2 independent experiments. Abbreviations as in Figure 1.
doi:10.1371/journal.pntd.0000794.g003
Drug Screening for Cryptosporidium
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have off-target activities in the parasite or the host cell will inhibit
the growth of all three strains. A general inhibitor of both
prokaryotic and eukaryotic IMPDHs will block the proliferation of
both T. gondii-CpIMPDH and T. gondii-DHXGPRT in the
presence of xanthine, but will have no effect on the wild-type
strain which contains HGXPRT (note that such compounds
should be detected in our enzyme assays and eliminated before
they reach this screen). Lastly, compounds showing poor efficacy
against the T. gondii-CpIMPDH parasite may signal problems
pertaining to compound uptake, stability or metabolism. Examples
of these varied outcomes are discussed below.
A high-content imaging assay to evaluate anti-
cryptosporidial activity of compounds
While the Toxoplasma model provides outstanding throughput
and an excellent first filter it does not model all aspects of
Cryptosporidium biology. A direct and efficient assay of Cryptospo-
ridium proliferation was also needed. Fluorescent Vicia villosa lectin
(VVL) has been used previously to score C. parvum growth by
fluorescence microscopy [43–45]. VVL binds with high specificity
to the C. parvum parasite, labelling sporozoites, the inner oocyst
wall, and most importantly intracellular stages [40,44,45] but not
the outer oocyst wall [46]. To accommodate the increasing
number of compounds entering the SAR pipeline, we adapted the
FITC-VVL immunofluorescence assay to a 96-well plate format
and developed an automated imaging and analysis pipeline.
Figure 4 shows an overview of the methodology. Plates are fixed,
permeabilized and stained with FITC-VVL and DAPI to
enumerate parasites and host cells, respectively. Using a spinning
disc high-content microscope a 1.08 mm
2 area of each well, was
imaged providing a robust sample typically consisting of ,6000
host cells and ,2000 parasite stages. The instrument is
programmed to automatically move from well to well, focus
and acquire 20 mm deep image stacks for the entire plate. A series
of automated image compression, manipulation, and object-
finding algorithms was optimized for the recognition of host cells
and parasites using the DAPI and FITC channels respectively
(Figure 4 A and B, see Materials and Methods for further detail).
To normalize for background staining and biological variability,
control wells are included for background subtraction. The
massive data output is stored, managed and accessed through an
Accelrys pipeline database that performs further statistical
analyses and transforms raw counts into percentage growth
relative to a ‘‘no drug’’ control. Figure 4C shows a 2-fold titration
of oocysts where the highest inoculum was 5.9610
5 oocysts per
well, for C. parvum growth assays 5610
5 oocysts were added per
well. Importantly, the algorithm can easily distinguish host and
parasite, so false positives are not an issue.
The inhibition of parasite proliferation by paromomycin was
evaluated to demonstrate the validity of this assay. The EC50 for
paromomycin measured with this assay was 97 mM (Figure 4D),
which is in good agreement with several previous studies
(reported EC50 values range from 65–130 mM [20,29,47,48]).
Perplexingly, a significant number of parasites are observed even
at very high concentrations of paromomycin (,30% relative to
the ‘‘no drug’’ control; Figure 4A). These residual parasites may
be a developmentally arrested subset of the initial inoculum (note
that a similar number of parasites is detected already after
24 hours, Figure S3). Interestingly, paromomycin was also found
to significantly reduce the mean parasite area in a dose respon-
sive manner (Figure 4D), which may also suggest arrested
development.
Validation of the fluorescent host cell growth assay
The differentiation of selective antiparasitic effects from those
that are a secondary consequence of a host cell effect is a critical
issue in drug discovery for intracellular parasites. Cytotoxicity
assays commonly reflect plasma membrane integrity, and are a
crude measure of host cell effects- it is conceivable that more subtle
perturbations of host cell metabolism can have an adverse effect on
parasite proliferation. Therefore we sought to develop a simple
and inexpensive assay of host cell growth. The human ileocecal
adenocarcinoma epithelial cell line, HCT-8, which is commonly
used to maintain C. parvum infection in tissue culture, was
engineered to constitutively express a green fluorescent protein
(GFP). Growth of this cell line was monitored daily using a
fluorescent plate reader. In agreement with previous reports [49–
51], paromomycin had negligible effects on the growth of these
cells (Figure S4A). The control sodium butyrate did inhibit HCT-8
growth in a dose-dependent manner in this assay (Figure S4B), as
anticipated due to previous reports of its apoptotic effects in
colonic tumor cell lines [52]. These experiments validate the use of
the fluorescent HCT-8 cell growth assay.
Identification of highly selective CpIMPDH inhibitors in
the T. gondii model
The antiparasitic activities of compounds from our medicinal
chemistry optimization program of compound A (identified in our
Figure 4. Overview and validation of the high content imaging
C. parvum growth assay. A, schematic representation of differential
labelling of parasite and host. B, detail of an exemplary micrograph
obtained through the screening routine. Numbers indicate object
identifies after segmentation analysis. C shows a 2-fold titration of
C. parvum oocysts where the top concentration was 5.9610
5 oocysts
per well. For D, the ratio of the number of FITC-VVL labelled parasites to
DAPI labelled host cell nuclei was used to standardize each well.
Percent C. parvum growth (solid line) was normalized to parasites
receiving DMSO alone. The paromomycin EC50 for C. parvum growth
was 97 mM. Paromomycin in addition to reducing parasite number also
reduces the average size of the parasite (dashed line). Mean parasite
area was measured for each treatment in triplicate. The percent area
was then calculated respective to the mean area of parasites receiving
DMSO alone. Data shows the mean of two independent experiments
set up with triplicate wells in a 96-well format.
doi:10.1371/journal.pntd.0000794.g004
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www.plosntds.org 6 August 2010 | Volume 4 | Issue 8 | e794Figure 5. Compound structures and summary of activities. N.A., not applicable; N.D., not determined; a. Selectivity=EC50(T. gondii-wild-type)/
EC50(T. gondii-CpIMPDH); b. Highest concentration tested; c. Synthesis described previous study [22]; d. Lowest concentration tested; e. Determined in earlier
study [20]; f. Determined using qPCR as described in [20]. Note that the structure and activities of additional amide derivatives of compound A are shown in
Figure S5.
doi:10.1371/journal.pntd.0000794.g005
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The structures of these compounds are shown in Figure 5
(triazoles) and Figure S5 (amides) alongside a summary of findings.
Three compounds, A30, A57 and A66, do not inhibit CpIMPDH
in vitro; as expected, none of these compounds selectively blocked
the growth of T. gondii-CpIMPDH (Figures S5 & S6A). The
remaining compounds inhibit CpIMPDH with values of IC50
ranging from 9 nM to 2.6 mM [22]. Figure 6A shows represen-
tative data for fourteen 1,2,3-triazole derivatives in the T. gondii
model; the remaining compounds are shown in Figure S6A. With
the exception of A23 and A31, all compounds inhibit the growth
of the T. gondii-CpIMPDH parasite with an EC50,10 mM
(Figures 6B & S6). Five of the 1,2,3-triazole derivatives, A100,
A102, A103, A109 and A110, exhibit selectivity $36-fold for the
T. gondii-CpIMPDH parasite over wild-type T. gondii (Figure 5).
Therefore the antiparasitic effects of these compounds can be
confidently attributed to the inhibition of CpIMPDH. A99 is $17-
fold selective and the remaining compounds range in selectivity
from 0.9–14-fold (Figure 5). These compounds have similar effects
on both wild-type and T. gondii-DHXGPRT parasites (Figure 5),
indicating that the low selectivity derives from off-target effects
unrelated to TgIMPDH.
Surprisingly, initially we did not observe a significant correlation
between the potency of a compound in the enzyme assay and
inhibition of T. gondii-CpIMPDH proliferation (Figure 7A). We
wondered if some compounds might be binding nonspecifically to
Figure 6. Identification of derivatives with high potency and selectivity in the T. gondii-CpIMPDH model. A shows EC50 values for a
selection of inhibitors assayed in the T.gondii-CpIMPDH parasite model and demonstrates a range in inhibitor selectivity and potency. Compounds
were assayed in triplicate and growth inhibition was calculated on a day during the exponential phase of growth, by normalisation to wells receiving
DMSO alone. The EC50 calculation was performed as described in Figure S2. Compounds A82, A89, A90, A92, A102, A103, A105, and A110 were
selected for rescreening and the mean values for at least 2 replicate experiments are shown. The inhibitors were then tested for inhibition of
C. parvum (B) and host cell growth (C). For B percent C. parvum growth was determined using the high-content imaging assay as detailed in Figure 4,
with the inhibitor at 12.5 mM and 25 mM. A subset of compounds was selected for re-screening and the mean over at least 2 replicate experiments is
shown for compounds A90, A92, A98, A103, A105, A109 and A110. C shows percent host cell growth assayed using the fluorescent HCT-8 cell
line with inhibitors at 12.5 mM and 25 mM. GFP expressing HCT-8 cells were seeded at 4000 cells per well into 96-well plates and triplicate wells were
spiked with test compound and fluorescence was measured daily for 7 days. Percent growth inhibition was calculated on a day during the
exponential phase of growth, by normalisation to wells receiving DMSO alone. Inhibitors A89, A90 and A92 were selected for re-screening and the
mean over at least 2 replicate experiments is shown.
doi:10.1371/journal.pntd.0000794.g006
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also evaluated in the presence of BSA [22]. A strong positive
correlation is observed between inhibition of T. gondii-CpIMPDH
proliferation and potency of enzyme inhibition in the presence of
BSA (Figure 7B; r=0.94, p,0.0001). Selectivity in the T. gondii
model also correlates well with the potency of enzyme inhibition in
the presence of BSA (Figure 7C; r=20.92, p,0.0001). These
observations indicate that the IC50 value in the presence of BSA is
a useful proxy for antiparasitic activity modelled by T. gondii-
CpIMPDH proliferation.
The T. gondii model predicts off-target host cell effects
Host cell growth was also assayed to assess the contribution of
host cell effects to antiparasitic activity (Figures 6C and S6B). In
general, strong host cell effects are observed in compounds that
display little selectivity in the T. gondii model (Figures 5 & S5). With
few exceptions, compounds that inhibited the proliferation of wild-
type T. gondii with EC50#10 mM also inhibited the proliferation of
host cells. Compounds A82, A90 and A105 have values of
EC50#10 mM for all three Toxoplasma strains, and do not inhibit
Figure 7. Correlation between CpIMPH enzyme inhibition and
potency and selectivity in the T. gondii-CpIMPDH model. A
shows a relatively weak (r=0.58) and statistically insignificant (p-
value=0.3) correlation between the triazole compound IC50 values for
the CpIMPDH enzyme inhibition and the EC50 for proliferation of the
T. gondii-CpIMPDH parasite. However, a strong, positive correlation
exists between the potency of CpIMPDH enzyme inhibition when
assayed in the presence of BSA and inhibition of T. gondii-CpIMPDH
proliferation (r=0.94, p,0.0001; B). C, shows that selectivity in the
T. gondii model, determined by the relative inhibition of the T. gondii-
CpIMPDH parasite over wild-type T. gondii, also correlates well with the
potency of enzyme inhibition in the presence of BSA (r=20.92,
p,0.0001).
doi:10.1371/journal.pntd.0000794.g007
Figure 8. Compounds A103 and A110 are potent inhibitors of
C. parvum growth. C. parvum growth was determined using the HCI
assay. The ratio of the number of FITC-VVL labelled C. parvum parasites
to DAPI labelled HCT-8 host cell nuclei was used to standardize each
well and percent C. parvum growth was normalised to parasites
receiving DMSO alone. A and B show compounds A103 and A110
respectively (EC50,0.8 mM). Data shows the mean of two independent
experiments with triplicate wells.
doi:10.1371/journal.pntd.0000794.g008
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result from the inhibition of CpIMPDH or TgIMPDH. Instead,
these compounds may act on other T. gondii targets not present in
the host cell. Conversely, A100, A102, and A103 have EC50so f
$20 mM against wild-type T. gondii yet inhibit HCT-8 cell growth
significantly at 12.5 mM and 25 mM (Figure 5).
The anti-cryptosporidial activities of CpIMPDH inhibitors
The high-content imaging assay was used to evaluate the anti-
cryptosporidial activity of the 1,2,3-triazole CpIMPDH inhibitors
at 12.5 mM and 25 mM (Figure 6B). All compounds inhibited
C. parvum growth by at least 48% at a concentration of 25 mM
(Figure 6B) and thus had equal or markedly improved antic-
ryptosporidial efficacy when compared to parent compound A
[20]. Unlike paromomycin, a significant reduction in parasite area
was not detected (data not shown). The average area of the host
cell nucleus was also recorded as a potential indicator of host cell
cytotoxicity and likewise no significant change in host cell nuclei
size was detected (data not shown). Encouragingly there was a
negative trend between anticryptosporidial activity and host cell
growth inhibition (data not shown), indicating that improvements
in anticryptosporidial activity are not coincident with secondary
effects on the host cell.
To provide quantitative data to the SAR pipeline, the values of
EC50 were determined for seven compounds. A82, A90, A92, A98
and A105 had EC50 values between 3 mM and 13 mM (Figure 5).
Compounds A103 and A110 were found to be potent inhibitors of
C. parvum growth with EC50 values of ,0.8 mM (Figure 8A & B).
As shown above, A103 and A110 also have negligible effects on
host cell growth and exhibit good selectivity in the T. gondii model.
Therefore, A103 and A110 have improved specificity and efficacy,
and are promising candidates for advancement into mouse models
of infection.
While not every compound that showed activity against the
T. gondii-CpIMPDH parasite had strong anticryptosporidial
activity, none of the compounds showing poor activity in the
T. gondii-CpIMPDH model display significant anticryptosporidial
activity. The T. gondii assay also immediately flagged compounds
with poor permeability or off-target effects. We conclude that the
T. gondii-CpIMPDH model provides valuable information regard-
ing antiparasitic activity and is a fast and highly informative filter
for compound progression through medicinal chemistry optimi-
zation.
Conclusions
Despite the tremendous public health impact of cryptospo-
ridiosis, efforts to develop new and more effective treatments for
this disease have been languishing. There are a number of
reasons for this, but lack of suitable tissue culture and animal
models to assess drug candidates is currently the most
prominent roadblock. To overcome this challenge, we have
developed a facile screening pipe l i n et oe v a l u a t et h ea n t i p a r a -
sitic activity of CpIMPDH inhibitors. The backbone of this
pipeline is provided by a T. gondii model parasite that mirrors
Cryptosporidium purine nucleotide pathways and depends on
CpIMPDH. The T. gondii model reliably eliminates compounds
from further consideration and provides a useful filter to identify
off-target activities. However, efficacy in the T. gondii model
does not always guarantee anti-cryptosporidial activity. This
disparity likely arises from differences in the biology of the two
parasites. T. gondii and C. parvum infect different tissues, and
occupy different intracellular compartments. The parasitophor-
ous membrane of T. gondii is in direct contact with the host cell
cytoplasm [53]. In contrast, C. parvum remains beneath the
apical membrane of the host cell and is considered ‘extra-
cytoplasmic’ due to the presence of a parasite induced host cell
actin patch along with other peculiar and still largely
uncharacterized structures, including the feeder organelle and
a dense band visible in electron micrographs [54,55]. These
structures separate the parasite’s parasitophorous vacuole from
the host cell cytoplasm [56] and have been hypothesized to be
involved in drug and nutrient uptake [57]. Furthermore, the two
parasites, and their respective host cells, have different
repertoires of drug efflux transporters [58], which may also
account for the differences in inhibitor sensitivity. While the
T. gondii assay does not fully negate the necessity of testing in
Cryptosporidium directly, it has proven indispensible to winnowing
candidate compounds to a number amenable to this more
challenging model. We have used the pipeline to identify two
promising candidates for anticryptosporidial chemotherapy:
A103 and A110. These compounds are .1006 more potent
than paromomycin, the current standard for anticryptosporidial
activity.
Supporting Information
Figure S1 Schematic overview of TOXOU05 cosmid
recombineering. Open triangles show positions of 50 bp gene
specific primer sequences used to guide recombination in E. coli.
See [34] for additional technical detail and reference.
Found at: doi:10.1371/journal.pntd.0000794.s001 (0.22 MB TIF)
Figure S2 Obtaining an EC50 value for T. gondii growth.
Fluorescent T. gondii parasites are seeded into 96-well plates and
spiked with test compound. Fluorescence is measured daily with a
SpectraMax M22/M2e (Molecular Devices) plate reader for 6–7
days. The fluorescence readings on a day during the exponential
phase of the growth curve, for example day 4 in A, are used to
calculated percent growth inhibition. These values are fitted using
the 4 parameter model y=D+(A–D)/(1+(x/C)
B) where D is the
minimum value, A is the maximum value, C is the EC50 and B is
the Hill coefficient, using the SoftMax Pro v5 software, as
illustrated in B. The absolute EC50 is recorded at the x intercept
where y=50.
Found at: doi:10.1371/journal.pntd.0000794.s002 (0.33 MB TIF)
Figure S3 Time-course of VVL C. parvum growth assay.
HCT-8 cells were infected with C. parvum oocysts and the ratio of
parasites to host cell nuclei was measured using the VVL assays as
detailed in Fig. 4 after 1 or 2 days. Wells were either left uninfected
(squares), were infected and treated with paramomycin (circles), or
infected and treated with a DMSO solvent control (triangles).
Found at: doi:10.1371/journal.pntd.0000794.s003 (0.15 MB TIF)
Figure S4 Validation of the HCT-8 pmaxGFP host cell
growth assay. HCT-8 cells constitutively expressing GFP seeded
at 4000 cells per well into 96-well plates and triplicate wells were
spiked with test compound. Fluorescence was measured daily with
a SpectraMax M22/M2e (Molecular Devices) plate reader (Ex
485, Em 530) for 7 days. A shows a titration of paromomycin and
B sodium butyrate.
Found at: doi:10.1371/journal.pntd.0000794.s004 (0.27 MB TIF)
Figure S5 Compound structures and summary of
activities. N.A., not applicable; N.D., not determined; a.
Selectivity=EC50(T. gondii-wild-type)/EC50(T. gondii-CpIMPDH);
b. Highest concentration tested; c. Synthesis described previous
study [22]; d. Lowest concentration tested; e. Determined in
earlier study [20]; f. Determined using qPCR as described in [20].
Found at: doi:10.1371/journal.pntd.0000794.s005 (5.26 MB TIF)
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www.plosntds.org 10 August 2010 | Volume 4 | Issue 8 | e794Figure S6 Antiparasitic activity of the A series in the
T. gondii model of Cryptosporidium infection. A shows the
EC50 for a selection of compounds assayed in the T.gondii-
CpIMPDH parasite model. Compounds were assayed in triplicate
and growth inhibition was calculated on a day during the
exponential phase of growth, by normalisation to wells receiving
DMSO alone. The EC50 calculation was performed as described
in Figure S2. Note the highest concentration tested in panel A was
for compound A30 was 20 mM. B shows percent host cell growth
assayed using the GFP fluorescent HCT-8 cell line with compound
at 25 mM and 50 mM.
Found at: doi:10.1371/journal.pntd.0000794.s006 (0.97 MB TIF)
Supplemental Materials S1 NMR spectra data for com-
pounds A61, A64, A68 and A99.
Found at: doi:10.1371/journal.pntd.0000794.s007 (0.03 MB
DOC)
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